Oakworth Capital’s Bristol-Myers Squibb Company Contingent Value Rights CELG.RT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3 | Hold |
125
| – | – | ﹤0.01% | 636 |
|
|
2025
Q1 | $6 | Hold |
125
| – | – | ﹤0.01% | 685 |
|
|
2024
Q4 | $6 | Hold |
125
| – | – | ﹤0.01% | 629 |
|
|
2024
Q3 | $6 | Hold |
125
| – | – | ﹤0.01% | 668 |
|
|
2024
Q2 | $5 | Hold |
125
| – | – | ﹤0.01% | 721 |
|
|
2024
Q1 | $7 | Hold |
125
| – | – | ﹤0.01% | 683 |
|
|
2023
Q4 | $11 | Hold |
125
| – | – | ﹤0.01% | 679 |
|
|
2023
Q3 | $12 | Hold |
125
| – | – | ﹤0.01% | 599 |
|
|
2023
Q2 | $14 | Hold |
125
| – | – | ﹤0.01% | 631 |
|
|
2023
Q1 | $15 | Hold |
125
| – | – | ﹤0.01% | 586 |
|
|
2022
Q4 | $15 | Hold |
125
| – | – | ﹤0.01% | 572 |
|
|
2022
Q3 | $0 | Hold |
125
| – | – | ﹤0.01% | 555 |
|
|
2022
Q2 | $0 | Hold |
125
| – | – | ﹤0.01% | 550 |
|
|
2022
Q1 | $0 | Buy |
+125
| New | – | ﹤0.01% | 545 |
|